These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7905033)

  • 1. Validation of the 16-item Negative Symptom Assessment.
    Axelrod BN; Goldman RS; Alphs LD
    J Psychiatr Res; 1993; 27(3):253-8. PubMed ID: 7905033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of instrument sensitivity to negative symptom change.
    Eckert SL; Diamond PM; Miller AL; Velligan DI; Funderburg LG; True JE
    Psychiatry Res; 1996 Jun; 63(1):67-75. PubMed ID: 8832775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
    Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
    Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of 2 depression scales and their relationship with negative and akinetic symptoms in stabilized schizophrenic patients].
    Langlois-Thery S; Dollfus S; Lesieur P; Petit M
    Encephale; 1994; 20(5):487-93. PubMed ID: 7828511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Training novice raters on the Negative Symptom Assessment Scale.
    Axelrod BN; Alphs LD
    Schizophr Res; 1993 Mar; 9(1):25-8. PubMed ID: 8461268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptom structure and severity: a comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia.
    Stefanovics EA; Krystal JH; Rosenheck RA
    Compr Psychiatry; 2014 May; 55(4):887-95. PubMed ID: 24602497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
    Loas G; Noisette C; Legrand A; Delahousse J
    Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conceptualizing schizophrenia through attenuated symptoms in the population.
    Carpenter WT
    Am J Psychiatry; 2010 Sep; 167(9):1013-6. PubMed ID: 20826849
    [No Abstract]   [Full Text] [Related]  

  • 9. Validation of a 4-item Negative Symptom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in schizophrenia.
    Alphs L; Morlock R; Coon C; Cazorla P; Szegedi A; Panagides J
    Int J Methods Psychiatr Res; 2011 Jun; 20(2):e31-7. PubMed ID: 21538654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation.
    Leucht S; Davis JM; Engel RR; Kissling W; Kane JM
    Acta Psychiatr Scand Suppl; 2009; (438):7-14. PubMed ID: 19132961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PANSS should be rescaled.
    Leucht S; Kissling W; Davis JM
    Schizophr Bull; 2010 May; 36(3):461-2. PubMed ID: 20357133
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical utility of the Negative Symptom Assessment-16 in individuals with schizophrenia.
    Rekhi G; Alphs L; Ang MS; Lee J
    Eur Neuropsychopharmacol; 2019 Dec; 29(12):1433-1441. PubMed ID: 31761524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive and negative symptoms: is their change related?
    Czobor P; Volavka J
    Schizophr Bull; 1996; 22(4):577-90. PubMed ID: 8938912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of symptoms in neuroleptic-naive patients with schizophrenia and related psychotic disorders before and after treatment.
    Peralta V; Cuesta MJ; Martinez-Larrea A; Serrano JF
    Psychiatry Res; 2001 Dec; 105(1-2):97-105. PubMed ID: 11740979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new five factor model of schizophrenia.
    Lindenmayer JP; Bernstein-Hyman R; Grochowski S
    Psychiatr Q; 1994; 65(4):299-322. PubMed ID: 7831416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Food and Drug Administration commentary on methodological issues in negative symptom trials.
    Laughren T; Levin R
    Schizophr Bull; 2011 Mar; 37(2):255-6. PubMed ID: 21245124
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive clonazepam in the treatment of chronic schizophrenia.
    Herrera JM; Alvarez WA; Freinhar JP; Lawson WB; Sramek JJ
    Int J Psychosom; 1991; 38(1-4):17-20. PubMed ID: 1685726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predictive value of psychopathological subclassifications for the neuroleptic treatment outcome in schizophrenia.
    Jarema M; Kacperczyk J; Kruszynski S
    Psychopathology; 1991; 24(3):141-6. PubMed ID: 1684443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multisite investigation of the reliability of the Scale for the Assessment of Negative Symptoms.
    Mueser KT; Sayers SL; Schooler NR; Mance RM; Haas GL
    Am J Psychiatry; 1994 Oct; 151(10):1453-62. PubMed ID: 7916540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.